PERCUTANEOUS TRANSLUMINAL AORTIC ANGIOPLASTY WITH STENTING FOR IN-STENT RESTENOSIS IN TAKAYASU’S ARTERITIS

Nandhakumar Vasu1, Jaishankar Krishnamoorthy2, Srinivasan Narayanan3, Mullasari Ajit Sankaradas4

1Junior Consultant, Department of Cardiology, Institute of Cardio-Vascular Diseases, Madras Medical Mission.
2Senior Consultant, Department of Cardiology, Institute of Cardio-Vascular Diseases, Madras Medical Mission.
3Consultant, Department of Cardiology, Institute of Cardio-Vascular diseases, Madras Medical Mission.
4Director & Senior Consultant, Department of Cardiology, Institute of Cardio-Vascular Diseases, Madras Medical Mission.

ABSTRACT

A 37-year-old female patient with coarctation of abdominal aorta and right axillary artery stenosis due to Takayasu’s arteritis underwent Percutaneous Transluminal Angioplasty [PTA] with stents. After one and a half years, she developed In-Stent Restenosis [ISR] of both stents in abdominal aorta and right axillary artery because of discontinuation of corticosteroid and reactivation of disease. She underwent successful repeat angioplasty and stenting for ISR of abdominal aorta. She was discharged with optimal pressure in the left upper limb was 110/90 mmHg and both lower limbs showed 150/100 mmHg. There were bruits in periumbilical and right axillary regions. On examination of cardiovascular system, there was a left ventricular S4 and no murmurs.

ECG revealed left ventricular hypertrophy. Her haemoglobin was 9.7 g/dL, PCV-30.5%, ESR 51 mm/hour and biochemistry was within normal limits. There was left ventricular hypertrophy and good biventricular function on echocardiogram.

Two years ago, she had undergone PTA and Stent deployment to right axillary artery using 7 x 60 mm complete SE iliac Medtronic stent and abdominal aorta was stented using 14 x 80 cm COOK ZILVER 635 and 14 x 60 cm COOK ZILVER 635 two self-expanding stents, which was expanded up to 9 mm. She was put on three antihypertensive medications [Extended release nifedipine 20 mg once daily, metoprolol 50 mg twice daily and alpha methyl dopa 500 mg twice daily] along with prednisolone 40 mg once a day, dual antiplatelets [Aspirin and clopidogrel] and pantoprazole. Also she was advised to review after 6 months for graded dilatations of aortic stents. But she lost for follow-up and stopped corticosteroids.

CT aortogram during the present admission showed diffusely narrowed abdominal aortic stent [Fig. 1A and 1B] tightest lesion at the distal end of stent and totally occluded right axillary artery stent and distal vessel was filling via collaterals.

Through right femoral approach, aortogram was done to delineate aortic stent and abdominal aortic branches. Pressure gradient was checked from the proximal end of stent in descending aorta up to aorto-iliac bifurcation using 5F Multi-Track catheter. There was significant increase in gradient towards lower end of abdominal aortic stent extending after the stent distally at superior mesenteric arterial level. Serial dilatations were done at the mid and distal end of the stent using 8 x 20 mm conquest pro-balloon followed by 10 x 20 mm conquest pro-balloon. Gradients were recorded after balloon dilatations. A 9 x 57 mm Express LD balloon expandable stent was deployed across the distal end of abdominal aortic stent.
extending up to superior mesenteric arterial level. Final angiogram showed minimal gradient with well-opposed stent without any dissection or flap [Fig. 2A and 2B].

Patient was discharged with dual antiplatelets, antihypertensive drugs [Amlodipine 10 mg once daily, hydrochlorothiazide 12.5 mg once daily, metoprolol 50 mg twice daily and alpha methyladop 500 mg twice daily] along with 40 mg of prednisolone and pantoprazole with the plan of axillary artery stenting as a staged procedure. On follow-up at 3 months, she is symptomatically better with an ESR of 31 mm per hour.

<table>
<thead>
<tr>
<th>Site</th>
<th>Pre-Procedure (mmHg)</th>
<th>Post-Procedure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above the Stent at Thoracic Aorta</td>
<td>215/86/138</td>
<td>263/104/170</td>
</tr>
<tr>
<td>Proximal Stent</td>
<td>215/86/138</td>
<td>253/99/158</td>
</tr>
<tr>
<td>Proximal End of the Second Stent</td>
<td>150/76/103</td>
<td>231/96/151</td>
</tr>
<tr>
<td>Lower End of the Second Stent</td>
<td>125/74/97</td>
<td>227/90/147</td>
</tr>
<tr>
<td>Femoral Artery</td>
<td>90/58/72</td>
<td>228/92/140</td>
</tr>
</tbody>
</table>

**Pressure Recordings Before and After PTA**

**DISCUSSION**

Takayasu’s arteritis is a chronic inflammatory arteritis affecting large vessels, predominantly the aorta and its main branches. It is also known as pulseless disease, occlusive thromboaortopathy and Martorell syndrome. Vessel inflammation leads to wall thickening, fibrosis, stenosis and thrombus formation, whereas acute inflammation can destroy the arterial media and lead to aneurysm formation. It is most commonly seen in Japan, South East Asia, India and Mexico. In 1990, it was included in the list of intractable diseases maintained by the Japanese government.

Although medical management with corticosteroids has been widely used to control the inflammation, revascularization must be considered when the symptoms become resistant to medication. Many surgical techniques have been reported, but they carry high morbidity and mortality rates and are associated with problems of stenosis or aneurysm formation at the anastomotic points.

PTA is a viable alternative to surgery with a low complication rate. However, post-PTA restenosis with Takayasu’s arteritis has been reported to occur much frequently than in association with atherosclerotic diseases, particularly in diffuse and long stenotic lesions. At present, stent placement has rapidly gained acceptance for the treatment of Takayasu’s arteritis; however, PTA for an In-Stent Restenosis (ISR) in association with Takayasu’s arteritis rarely been documented. In this patient, we planned to do staged dilatation of abdominal aortic stent. Unfortunately because of reactivation of disease due to poor drug compliance and loss of follow up, the patient developed ISR of both aortic and right axillary stents. She underwent redo PTA with stenting of aortic ISR and discharged with the plan of axillary stenting after 6 months. The corticosteroid was reintiated and she is planned for Mycophenolate mofetil should she develop resistance for steroids in future. It is important to control disease activity with newer immuno-suppressant like Mycophenolate mofetil, if it is not achieved by corticosteroids to prevent restenosis.

**CONCLUSION**

Redo PTA with stenting and optimal disease modifying drugs is a good option for symptomatic abdominal aortic ISR in Takayasu’s arteritis.

**REFERENCES**


